Phoenix Holdings Ltd. 89bio, Inc. Transaction History

Phoenix Holdings Ltd.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 10, 2021	SELL	$17.42 - $28.0 $246,493 - $396,200	-14,150 Closed	0 $0
Q1 2021 May 10, 2021	SELL	$20.22 - $26.73 $588,422 - $777,869	-29,101 Reduced 67.28%	14,150 $336,000
Q4 2020 Feb 11, 2021	BUY	$23.16 - $28.08 $220,020 - $266,760	9,500 Added 28.15%	43,251 $1.1 Million
Q3 2020 Nov 10, 2020	BUY	$24.34 - $38.82 $64,403 - $102,717	2,646 Added 8.51%	33,751 $798,000
Q2 2020 Aug 10, 2020	BUY	$19.93 - $31.2 $619,922 - $970,476	31,105 New	31,105 $588,000

159

108M

73.6K

1.19M

Ticker ETNB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,484,500
Market Cap $320M
Description
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also int...

Get notified when there are updates to the investment portfolio of Phoenix Holdings Ltd., based on Form 13F filings with the SEC.

Stay updated on Phoenix Holdings Ltd. with notifications on news.